recent
infecti
outbreak
highlight
need
platform
technolog
quickli
deploy
develop
therapeut
need
contain
outbreak
present
simpl
concept
rapid
develop
new
antimicrobi
goal
produc
littl
one
week
thousand
dose
intervent
new
pathogen
test
feasibl
system
base
antimicrobi
synbodi
system
involv
creat
array
peptid
select
broad
capabl
bind
andor
kill
virus
bacteria
peptid
prescreen
low
cell
toxic
prior
larg
scale
synthesi
pathogen
assay
chip
find
peptid
bind
kill
peptid
combin
pair
synbodi
screen
activ
toxic
lead
synbodi
quickli
produc
larg
scale
complet
entir
process
one
week
wide
recognit
need
develop
new
antibiot
histor
never
wide
select
effect
antivir
antivir
human
immunodefici
viru
hepat
b
hepat
c
influenza
herp
cytomegaloviru
avail
clinic
defici
develop
pipelin
magnifi
outbreak
new
pathogen
sever
acut
respiratori
syndrom
sar
middl
east
respiratori
syndrom
mer
caus
coronavirus
wider
emerg
known
pathogen
ebola
outbreak
west
africa
zika
viru
america
particularli
case
emerg
would
ideal
standard
readytorun
platform
develop
thousand
dose
new
antibiot
antivir
emerg
agent
short
time
new
agent
high
probabl
low
toxic
high
efficaci
would
decreas
time
use
emerg
present
concept
develop
antibiot
antivir
systemat
potenti
rapid
manner
base
synbodi
technolog
test
feasibl
design
fast
respons
system
appli
follow
requir
assum
infect
agent
isol
avail
may
requir
aliv
reliev
necess
highlevel
contain
requir
creation
therapeut
agent
could
accomplish
week
less
least
dose
produc
product
would
integr
simultan
toxic
screen
increas
probabl
approv
therapeut
requir
antibiot
antivir
oral
avail
emerg
intraven
administr
may
adequ
use
synbodi
technolog
start
point
develop
platform
meet
specif
synbodi
bival
peptid
antibodi
like
featur
chemic
synthes
two
peptid
bind
differ
region
chosen
target
usual
low
affin
specif
link
creat
high
affin
high
specif
reagent
two
arm
synbodi
chosen
premad
set
peptid
random
sequenc
space
array
slide
felt
modular
aspect
synbodi
might
lend
rapid
product
particularli
larg
number
dose
short
time
addit
surfac
viral
bacteri
pathogen
present
repeat
bind
element
provid
addit
avid
bival
synbodi
target
surfac
pathogen
detail
concept
test
feasibl
featur
produc
antibiot
antivir
system
overview
shown
bacteria
virus
appli
peptid
microarray
gener
synbodi
antibiot
antivir
activ
challeng
creat
system
gener
synbodi
quickli
provid
suffici
quantiti
chosen
synbodi
vivo
test
key
issu
publish
process
involv
appli
bacteri
target
peptid
microarray
k
choos
test
target
peptid
synthesi
larg
amount
two
candid
peptid
synthesi
synbodi
retest
process
usual
take
sever
month
ratelimit
step
synthesi
purif
larg
amount
candid
peptid
solut
time
issu
prescreen
larg
number
pathogen
k
peptid
microarray
arriv
peptid
would
offer
suffici
divers
pathogen
screen
would
bind
two
peptid
fig
select
peptid
somewhat
pathogen
specif
other
broadli
reactiv
abl
select
reduc
set
peptid
potenti
bind
new
pathogen
screen
peptid
would
practic
synthes
larg
stock
peptid
advanc
dose
therapeut
could
produc
quickli
microarray
develop
stock
synthes
would
start
point
develop
therapeut
shown
fig
pathogen
incub
microarray
peptid
bind
identifi
peptid
link
combin
creat
lead
synbodi
use
peptid
linker
stock
lead
screen
activ
target
prefer
block
activ
vitro
assay
candid
synbodi
produc
larg
amount
purifi
test
mice
acut
toxic
red
blood
cell
hemolysi
goal
integr
compon
step
whole
process
could
complet
week
creat
microarray
creat
librari
could
potenti
bind
pathogen
screen
differ
virus
bacteria
repres
wide
rang
pathogen
bacteria
virus
peptid
microarray
supplementari
tabl
k
array
consist
peptid
spot
duplic
standard
size
glass
microscop
slide
peptid
compos
variabl
amino
acid
ntermin
csgconstant
region
use
immobil
surfac
slide
surfac
coat
polym
increas
peptid
densiti
reduc
nonspecif
bind
peptid
featur
figur
develop
pathogen
bind
microarray
rapid
synbodi
discoveri
system
rang
pathogen
virus
bacteria
screen
librari
peptid
identifi
share
specif
pathogen
bind
peptid
total
peptid
select
secondari
bind
screen
downselect
cellular
toxic
peptid
confirm
bind
minim
toxic
select
inclus
pathogen
bind
peptid
microarray
b
workflow
discoveri
antimicrobi
synbodi
new
unknown
pathogen
fluoresc
label
screen
pathogen
bind
microarray
peptid
bind
pathogen
select
conjug
synbodi
scaffold
produc
synbodi
librari
activ
toxic
test
seri
vitro
function
assay
select
antimicrobi
synbodi
addit
develop
ic
stain
intracellular
stain
cw
stain
cell
wall
stain
known
sequenc
variabl
amino
acid
posit
peptid
compos
differ
amino
acid
slight
amino
acid
aromat
side
chain
supplementari
fig
bacteria
panel
screen
bind
peptid
one
two
way
live
bacteria
screen
use
previous
publish
method
inactiv
bacteria
detect
use
antibodi
specif
pathogen
live
bacteria
screen
assay
target
label
aminereact
dye
alexafluor
af
intern
dye
cell
tracker
orang
cto
peptid
bind
bacteria
without
perturb
membran
produc
fluoresc
channel
disrupt
membran
produc
fluoresc
af
channel
virus
screen
detect
bind
peptid
use
fluoresc
label
virusspecif
antibodi
case
directli
label
viru
alexa
fluor
dye
antibodi
detect
favor
avoid
problem
dye
interf
viru
bind
bind
peptid
microarray
data
analyz
bind
peptid
select
accord
follow
criteria
pathogen
detect
via
antibodi
peptid
signal
higher
antibodi
control
ii
direct
label
pathogen
peptid
signal
background
live
bacteria
peptid
afcto
select
strategi
yield
total
peptid
fig
heat
map
data
demonstr
peptid
bind
singl
organ
bind
multipl
pathogen
fig
supplementari
inform
organ
rel
peptid
hit
other
e
coli
peptid
pass
select
criteria
fig
major
peptid
bound
pathogen
peptid
bound
pathogen
fig
data
set
select
multipathogen
peptid
singl
pathogen
bind
peptid
total
peptid
could
maxim
cover
pathogen
space
peptid
synthes
three
plate
screen
secondari
assay
bind
toxic
peptid
synthes
mg
scale
ntermin
biotin
use
without
purif
supplementari
inform
librari
qualiti
analyz
mass
spectrometri
small
number
peptid
peptid
contain
fulllength
peptid
high
abund
analyz
mass
spectrometri
includ
subsequ
assay
reduc
librari
size
peptid
first
issu
confirm
peptid
bound
target
pathogen
previous
use
select
pathogen
bind
peptid
must
function
immobil
microarray
therefor
print
peptid
candid
new
microarray
use
method
k
array
screen
virus
bacteria
supplementari
tabl
previous
test
k
array
verifi
bind
appropri
pathogen
increas
confid
bind
data
chang
detect
method
sever
bacteri
pathogen
label
use
k
array
experi
dual
membran
label
approach
use
peptid
bound
array
detect
method
consid
true
hit
analysi
found
peptid
show
bind
pathogen
fig
supplementari
inform
peptid
test
elisa
assay
determin
rel
affin
four
differ
pathogen
vaccinia
viru
influenza
viru
gramneg
pathogen
f
tularensi
r
prowazekii
repres
result
peptid
bind
pathogen
present
fig
supplementari
fig
seen
peptid
show
high
bind
across
pathogen
test
concentr
indic
like
promiscu
nonspecif
bind
howev
peptid
concentr
depend
chang
pathogen
bind
absolut
k
valu
could
determin
method
unpurifi
peptid
use
rel
k
valu
could
estim
mani
peptid
exhibit
concentr
depend
bind
peptid
phenotyp
classifi
probabl
pathogen
binder
nonspecif
bind
nonbind
peptid
reject
total
peptid
pass
screen
parallel
bind
assay
peptid
screen
vitro
cytotox
assay
use
cell
peptid
screen
cell
viabil
plot
fig
peptid
exhibit
toxic
assay
nois
peptid
highest
toxic
reject
base
data
peptid
rank
array
bind
bind
pathogen
elisa
vitro
cytotox
total
peptid
show
bind
bind
assay
addit
peptid
show
bind
peptid
array
analysi
peptid
show
wide
distribut
net
charg
isoelectr
point
supplementari
fig
librari
cation
contrast
peptid
antimicrobi
peptid
amp
databas
cation
peptid
synthes
commerci
sigma
scale
purifi
puriti
supplementari
tabl
stock
sourc
peptid
print
peptid
array
synthesi
synbodi
confirm
unknown
pathogen
would
bind
peptid
reduc
librari
screen
two
pathogen
use
part
peptid
select
process
adenoviru
rotaviru
adenoviru
nonenvelop
doublestrand
dna
viru
rotaviru
nonenvelop
doublestrand
rna
viru
viru
label
test
use
procedur
fluoresc
signal
across
channel
compar
seen
multipl
peptid
bound
new
pathogen
fig
correl
fluoresc
dye
bind
peptid
new
pathogen
could
easili
identifi
exampl
peptid
rel
fluoresc
valu
fluorophor
could
select
bind
peptid
new
viru
way
multipl
peptid
could
select
synbodi
construct
data
indic
array
potenti
identifi
bind
peptid
given
pathogen
rapid
synbodi
discoveri
creation
microarray
allow
implement
select
process
shown
fig
pathogen
interest
appli
microarray
peptid
select
base
rel
floresc
seven
peptid
select
peptid
stock
use
synthes
combin
peptid
synbodi
develop
modular
combinatori
approach
use
maleimidethiol
conjug
rapidli
produc
synbodi
librari
select
peptid
conjug
differ
peptid
scaffold
two
conjug
site
combinatori
manner
parallel
approach
dozen
even
hundr
synbodi
produc
day
synbodi
evalu
potenc
efficaci
toxic
best
select
product
larg
scale
synbodi
produc
screen
pathogen
bind
elisa
vitro
activ
either
growth
inhibit
assay
antibacteri
plaqu
reduct
assay
antivir
synbodi
red
blood
cell
toxic
kidney
toxic
candid
high
target
bind
vitro
activ
low
toxic
prepar
larg
scale
mg
chemistri
purifi
hplc
parallel
primari
screen
rapid
synbodi
product
use
stock
premad
peptid
parallel
activ
toxic
test
enabl
system
produc
synbodi
candid
rapid
fashion
basic
compon
step
optim
test
run
specif
pathogen
execut
determin
time
complet
synbodi
product
chose
influenza
major
health
concern
worldwid
viral
test
epidermidi
caus
surgeri
relat
infect
sourc
antibiot
resist
gene
bacteri
target
test
princip
whether
antivir
synbodi
could
produc
protocol
focus
develop
viral
infect
inhibitor
pandem
influenza
screen
array
use
two
color
fluoresc
label
strategi
base
rel
bind
select
peptid
fig
test
abil
bind
hemagglutinin
ha
inhibit
hemagglutin
red
blood
cell
differ
concentr
peptid
inhibit
hemagglutin
bound
peptid
array
prevent
hemagglutin
even
higher
concentr
data
shown
base
hai
screen
peptid
use
prepar
synbodi
pairwis
conjug
previous
develop
synbodi
scaffold
synbodi
hydrolyz
prevent
thiolexchang
reaction
occur
maleimid
conjug
peptid
expos
excess
thiol
albumin
synbodi
test
hai
assay
exhibit
inhibit
fig
final
test
synbodi
prevent
viral
cell
entri
synbodi
neg
control
synbodi
test
plaqu
reduct
assay
fig
cell
treat
neutral
antibodi
inhibit
synbodi
exhibit
concentr
depend
decreas
plaqu
format
ic
respect
synbodi
test
hemolysi
concentr
roughli
time
ic
exhibit
less
hemolysi
supplementari
fig
indic
low
red
blood
cell
toxic
data
indic
new
viru
screen
small
peptid
librari
discov
bind
peptid
convert
neutral
synbodi
rapid
manner
develop
antibiot
data
present
indic
feasibl
develop
substanti
amount
synbodi
antivir
one
week
use
system
produc
synbodi
activ
bacterium
epidermidi
epidermidi
genu
aureu
use
primari
select
assay
larg
phenotyp
differ
epidermidi
aureu
well
consider
intra
strain
variat
peptid
select
prototyp
peptid
microarray
design
broadli
bind
pathogen
rather
kill
specif
bacteria
use
previous
demonstr
strategi
use
bind
peptid
conjug
kill
peptid
produc
synbodi
proofofprincipl
studi
epidermidi
screen
peptid
array
peptid
select
bound
epidermidi
predict
low
kill
activ
base
upon
afcto
ratio
fig
peptid
test
mic
inhibit
epidermidi
growth
um
shown
therefor
select
two
posit
binder
one
neg
control
peptid
conjug
aureu
lytic
peptid
call
ly
produc
small
synbodi
librari
test
inhibitori
activ
found
synbodi
inhibit
epidermidi
growth
um
expect
inhibit
bacteri
growth
mic
respect
fig
synbodi
test
hemolysi
um
hemolysi
observ
supplementari
fig
data
indic
synbodi
system
also
use
quickli
produc
antibacteri
candid
addit
develop
describ
strategi
employ
synbodi
platform
enabl
creation
dose
potenti
antibiot
antivir
week
first
develop
microarray
peptid
would
bind
one
pathogen
screen
divers
bacteria
virus
peptid
microarray
peptid
array
bound
multipl
pathogen
lytic
bacteria
chosen
screen
peptid
synthes
assess
bind
pathogen
panel
elisatyp
bind
vitro
toxic
human
cell
librari
peptid
chosen
synthes
purifi
larg
scale
peptid
print
small
microarray
core
rapid
screen
system
rapidli
synthes
screen
synbodi
demonstr
demonstr
project
synbodi
valu
repres
mean
sem
six
replic
spot
per
peptid
background
bind
measur
empti
spot
bkgd
peptid
hit
mean
bind
significantli
higher
p
neg
control
peptid
b
inhibit
hemagglutin
synbodi
error
bar
repres
standard
error
replic
assay
c
plaqu
reduct
infect
mdck
cell
candid
synbodi
neutral
mab
use
posit
control
three
hai
inhibit
nonhai
inhibit
synbodi
test
error
bar
repres
standard
error
replic
assay
influenza
viru
effect
vitro
produc
process
use
produc
antibiot
epidermi
one
week
inhibit
growth
previous
demonstr
synbodi
could
develop
antibiot
activ
shown
valu
use
amino
acidcontain
peptid
challeng
address
whether
process
could
done
quickli
key
develop
microarray
repres
enough
broad
pathogenbindinglyt
space
allow
us
prestock
larg
amount
peptid
combinatori
product
synbodi
note
cost
synthesi
peptid
decreas
notabl
economi
scale
enabl
commerci
product
numer
peptid
therapeut
second
new
featur
develop
system
rapid
synthesi
screen
candid
synbodi
requir
optim
conjug
chemistri
third
new
aspect
incorpor
rapid
toxic
screen
underli
assumpt
approach
pathogen
surfac
space
enough
redund
differ
peptid
could
cover
divers
true
impli
pathogen
divers
bacteria
virus
overlap
chemic
divers
pathogen
screen
infecti
agent
possibl
human
pathogen
evolv
human
immun
system
constrain
surfac
divers
pathogen
analysi
peptid
sequenc
reveal
obviou
trend
common
motif
would
suggest
target
specif
pathogen
homolog
natur
receptor
altern
peptid
predict
lack
secondari
structur
given
random
amino
acid
distribut
length
therefor
could
bind
target
compar
affin
differ
mechan
action
current
investig
demand
time
allow
us
incorpor
one
synbodi
relat
technolog
shown
candid
peptid
could
greatli
improv
affin
refin
select
featur
done
make
matrix
singl
amino
acid
variant
screen
increas
affin
simpli
addit
variant
howev
rel
process
addit
step
would
add
least
week
larg
due
time
synthesi
iter
natur
optim
method
time
requir
may
accept
addit
circumst
emerg
wish
test
limit
process
demonstr
b
synbodi
test
epidermidi
growth
inhibit
treatment
indic
concentr
exampl
outlin
process
describ
might
appli
situat
like
ebola
outbreak
west
africa
first
step
would
appli
intact
ebola
viru
array
could
done
use
high
titer
inactiv
blood
sera
facil
viru
bind
peptid
would
detect
use
label
antiebola
antibodi
total
assay
time
less
day
process
would
identifi
peptid
would
use
creat
panel
synbodi
conjug
reaction
synbodi
would
perform
parallel
proceed
complet
within
hour
purif
synbodi
perform
hplc
parallel
synbodi
could
screen
bind
inactiv
ebola
viru
facil
cell
toxic
hemolysi
screen
could
done
parallel
posit
candid
would
screen
inactiv
viru
cellbas
assay
would
requir
contain
two
best
candid
could
synthes
larg
stock
purifi
presum
synbodi
could
test
anim
model
safeti
protect
challeng
model
system
sever
limit
though
even
danger
pathogen
screen
facil
kill
activ
screen
would
conduct
live
pathogen
higher
contain
screen
kill
viabl
virus
probabl
matter
howev
screen
kill
bacteria
would
discrimin
lytic
peptid
case
may
requir
attach
bacteri
kill
element
bind
synbodi
exampl
other
explor
use
ligand
recruit
exist
antibodi
pathogen
final
synbodi
produc
process
would
probabl
oral
administr
unless
formul
howev
may
use
intraven
inject
possibl
biggest
concern
employ
system
product
peptidebas
therapeut
antimicrobi
peptid
amp
poor
track
record
produc
clinic
product
antibiot
daptomycin
vancomycin
colistin
peptid
addit
clinic
approv
hiv
fusion
inhibitor
enfuvirtid
peptid
elimin
halflif
hour
mani
standard
method
improv
proteas
stabil
peptid
therapeut
includ
incorpor
damino
acid
would
use
futur
implement
system
demonstr
potenti
workflow
produc
dose
antiinfect
produc
enough
product
populationwid
use
would
requir
substanti
scale
product
peptid
purif
synbodi
howev
even
focus
rapid
use
antiinfect
could
use
exampl
ebola
outbreak
protect
healthcar
worker
major
concern
zika
outbreak
concern
women
might
becom
pregnant
consid
synbodi
antibiot
antivir
similar
antibodi
therapeut
amp
antibodi
serum
therapi
use
antivir
antibacteri
treatment
number
monoclon
polyclon
antibodi
approv
argu
antibodi
revisit
mode
treat
infect
particularli
light
increas
antibiot
resist
clearli
cost
would
major
concern
broad
use
antibodi
regard
synbodi
may
advantag
less
expens
chemic
synthes
biolog
produc
antibodi
uniqu
featur
use
peptid
synbodi
scaffold
platform
produc
synbodi
direct
antibiot
antivir
activ
use
primari
secondari
infect
summari
demonstr
feasibl
produc
candid
antibiot
antivir
short
time
scale
preinvest
even
wider
select
peptid
candid
could
use
select
microarray
dose
candid
made
featur
demonstr
exampl
rapid
synthesi
larg
number
synbodi
candid
could
also
use
standard
approach
therapeut
develop
altern
parallel
advanc
high
densiti
peptid
microarray
synthesi
rapid
peptid
synthesi
could
dramat
increas
divers
peptid
screen
decreas
time
synthes
result
hit
emerg
technolog
could
elimin
need
librari
presynthesi
yet
maintain
speed
discoveri
platform
increas
potenti
approach
peptid
microarray
glass
microscop
slide
coat
polyethylenimin
prior
peptid
print
order
creat
high
densiti
peptid
surfac
featur
sulfosuccinimidyl
nmaleimidomethyl
sulfosmcc
appli
amin
surfac
activ
microarray
prior
print
peptid
peptid
amino
acid
long
csg
linker
nterminu
ntermin
cy
function
conjug
site
peptid
microarray
cystein
exclud
variabl
region
peptid
sequenc
gener
random
number
gener
minor
amino
acid
bias
peptid
synthes
sigma
custom
peptid
woodland
tx
use
without
purif
peptid
dilut
mgml
acid
hepe
ph
acetonitril
accn
prior
dispens
peptid
print
appli
microarray
inc
temp
az
use
noncontact
piezo
print
humid
array
wash
accn
methanol
meoh
wash
water
ddh
hour
prior
use
peptid
microarray
screen
peptid
microarray
block
block
buffer
bovin
serum
albumin
bsa
mgml
mercaptohexanol
tri
buffer
salin
tb
humid
chamber
hour
room
temperatur
microarray
wash
wash
buffer
tb
follow
two
wash
ddh
viru
solut
prepar
dilut
buffer
mgml
bsa
proteas
inhibitor
appli
peptid
microarray
incub
agil
microarray
chamber
hour
microarray
wash
probe
appropri
detect
antibodi
agil
microarray
chamber
hour
wash
probe
nm
conjug
secondari
antibodi
hour
array
wash
dri
scan
agil
microarray
scanner
sampl
run
duplic
array
primari
antibodi
screen
absenc
pathogen
neg
control
data
analyz
microsoft
excel
jmp
pro
bacteria
bind
use
previous
publish
method
synbodi
librari
product
synbodi
produc
accord
develop
method
synbodi
scaffold
synthes
sigma
custom
peptid
puriti
use
briefli
peptid
scaffold
separ
dissolv
accn
one
equival
scaffold
mix
two
equival
peptid
ph
reaction
mixtur
adjust
addit
dilut
trimethylamin
tea
accn
reaction
incub
room
temperatur
monitor
hplc
maldim
synbodi
purifi
hplc
molecular
weight
confirm
maldi
lyophil
prior
use
peptid
elisa
assay
nunc
maxisorp
flat
bottom
well
elisa
plate
coat
well
pathogen
elisa
coat
buffer
kept
overnight
plate
wash
three
time
phosphat
buffer
salin
pbst
use
biotek
plate
washer
follow
block
bsa
pbst
hour
plate
wash
biotin
label
peptid
ad
dilut
buffer
bsa
pbst
vv
incub
hour
plate
wash
streptavidinhorseradish
peroxidas
hrp
ad
incub
hour
plate
wash
tmb
thermo
scientif
ad
incub
dark
minut
room
temperatur
reaction
quench
hydrochlor
acid
hcl
read
immedi
nm
use
micropl
reader
spectra
max
molecular
devic
inc
peptid
exhibit
concentr
depend
bind
screen
appropri
concentr
confirm
pathogen
bind
desir
concentr
dispens
steril
tissu
cultur
plate
cell
ad
well
cell
incub
overnight
humid
order
remov
residu
ldh
activ
cell
overnight
assay
media
replac
new
media
peptid
dilut
time
final
concentr
assay
media
dispens
separ
plate
peptid
dispens
duplic
triplic
well
cell
contain
plate
along
appropri
control
incub
hour
humid
supernat
care
remov
transfer
optic
clear
flat
bottom
micropl
freshli
prepar
ldh
reaction
mixtur
roch
dispens
well
incub
min
stop
reaction
stop
solut
ad
well
absorb
sampl
measur
use
micropl
reader
spectra
max
molecular
devic
inc
cytotox
calcul
accord
manufactur
recommend
cell
viabil
replic
well
calcul
cytotox
hemagglutin
assay
initi
hemagglutin
assay
done
determin
titer
use
subsequ
hemagglutin
inhibit
repeat
new
turkey
red
blood
cell
trbc
lot
initi
pb
solut
ad
well
use
plate
initi
titer
bei
resourc
ad
duplic
concentr
viru
serial
dilut
fold
dilut
across
plate
solut
trbc
innov
research
cat
ad
plate
incub
minut
room
temperatur
incub
plate
check
hemagglutin
posit
hemagglutin
result
determin
appear
diffus
red
color
across
well
neg
result
appear
dot
center
round
bottom
plate
ha
titer
determin
highest
dilut
factor
caus
posit
hemagglutin
result
minimum
ha
concentr
label
hau
unit
subsequ
test
new
lot
trbc
follow
procedur
except
start
viru
concentr
hemagglutin
inhibit
hai
assay
viral
titer
previous
determin
use
initi
assay
candid
peptid
pb
ad
well
plate
peptid
solut
pb
ad
prior
serial
dilut
across
row
fold
dilut
twentyf
dilut
ad
well
achiev
concentr
hau
plate
incub
minut
room
temperatur
trbc
ad
plate
incub
minut
hemagglutin
measur
minimum
inhibitori
concentr
peptid
defin
highest
concentr
produc
neg
hemagglutin
result
subsequ
assay
run
start
synbodi
dilut
across
row
plaqu
reduct
neutral
assay
madindarbi
canin
kidney
cell
mdck
grown
plate
cellswel
influenza
pfu
incub
serial
dilut
synbodi
minim
essenti
medium
mem
gibco
hour
mixtur
transfer
onto
mdck
cell
plate
incub
hour
co
incub
viru
synbodi
mixtur
remov
cell
overlaid
agarosemem
medium
supplement
tpcktrypsin
sigma
infect
mdck
cell
cultur
day
co
fix
formaldehyd
stain
crystal
violet
number
plaqu
form
unit
determin
percentag
plaqu
reduct
calcul
base
pfu
produc
viru
without
treatment
monoclon
antibodi
serial
dilut
synbodi
use
posit
neg
control
monoclon
antiinfluenza
viru
antibodi
obtain
bei
resourc
niaid
nih
monoclon
antiinfluenza
viru
hemagglutinin
ha
clone
produc
vitro
assay
repeat
least
three
time
independ
data
repres
sem
mic
assay
determin
bacteri
growth
inhibit
use
adapt
version
broth
microdilut
method
peptid
synbodi
dilut
pb
ad
triplic
well
bacteri
suspens
cfuml
muellerhinton
broth
mhb
polypropylen
plate
plate
incub
shake
overnight
od
measur
use
micropl
reader
visibl
growth
defin
od
growth
rel
untreat
control
assay
perform
duplic
hemolyt
assay
red
blood
cell
toxic
measur
use
previous
publish
hemolyt
assay
experi
follow
anim
use
protocol
r
review
approv
arizona
state
univers
institut
anim
care
use
committe
experi
perform
accord
relev
guidelin
regul
briefli
blood
femal
balbc
mice
collect
via
termin
bleed
centrifug
g
minut
sera
discard
red
blood
cell
rins
three
time
vv
rbc
pb
centrifug
g
minut
wash
rbc
dilut
pb
dispens
triplic
well
plate
synbodi
sampl
ddh
posit
control
pb
neg
control
ad
well
plate
allow
incub
hour
plate
centrifug
g
minut
supernat
well
remov
dispens
new
well
titer
plate
absorb
nm
measur
percent
hemolysi
calcul
use
follow
formula
percent
hemolysi
avg
sampl
absorbanceavg
control
absorb
assay
perform
duplic
